Long-Term Efficacy and Safety of Paliperidone 6-Month Formulation: An Open-Label 2-Year Extension of a 1-Year Double-Blind Study in Adult Participants With Schizophrenia

被引:11
作者
Najarian, Dean [1 ]
Turkoz, Ibrahim [2 ,8 ]
Knight, R. Karl
Galderisi, Silvana [3 ]
Lamaison, Hector F. [4 ]
Zalitacz, Piotr [5 ]
Aravind, Suresh [2 ,7 ]
Richarz, Ute [6 ]
机构
[1] Janssen Sci Affairs LLC, Titusville, NJ USA
[2] Janssen Res & Dev LLC, Titusville, NJ USA
[3] Univ Campania Luigi Vanvitelli, Naples, Italy
[4] Natl Univ La Plata UNLP, Dept Psychiat, Buenos Aires, Argentina
[5] Gorlice Specialist Hosp, Psychiat Unit, Gorlice, Poland
[6] Cilag Int, Janssen Res & Dev, Gubelstr, Zug, Switzerland
[7] Dural Consulting LLC, St Petersburg, FL USA
[8] Janssen Res & Dev LLC, 1125 Trenton Harbourton Rd, Titusville, NJ 08560 USA
关键词
Long-term efficacy; schizophrenia; long-acting injectable; open-label extension; paliperidone palmitate 6-month; ACTING INJECTABLE ANTIPSYCHOTICS; PALMITATE; RELAPSE; REHOSPITALIZATION; NONADHERENCE; MEDICATION; ADHERENCE; PLACEBO;
D O I
10.1093/ijnp/pyad028
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Paliperidone palmitate 6-month (PP6M) demonstrated noninferiority to paliperidone palmitate 3-month in preventing relapse in patients with schizophrenia in a phase 3 double-blind (DB) study (NCT03345342). Here, we report long-term efficacy and safety results from a 2-year single-arm, open-label extension (OLE; NCT04072575) of this DB study. Methods Participants who completed the DB study without relapse were enrolled and followed-up every 3 months up to 2 years. Participants received 4 PP6M gluteal injections (700/1000 mg eq.) at baseline, 6-month, 12-month, and 18-month visits. Efficacy endpoints included assessment of relapse, Positive and Negative Syndrome Scale total score, Personal and Social Performance score, and Clinical Global Impression-Severity scale change from baseline. Safety was assessed by treatment-emergent adverse events (TEAEs), physical examinations, and laboratory tests. Results Of 178 participants enrolled, 154 (86.5%) completed the OLE (mean age: 40.4 years, men: 70.8%; mean duration of PP6M exposure during OLE: 682.1 days). Overall, 7/178 (3.9%) participants relapsed between 20 and 703 days after enrolment. Mean (SD) changes from baseline to endpoint were as follows: Positive and Negative Syndrome Scale total score, 0.7 (8.22); Clinical Global Impression-Severity, 0.0 (0.51); and Personal and Social Performance Scale, 0.5 (7.47). Overall, 111/178 participants (62.4%) reported & GE;1 TEAE; most common (>5%) TEAEs were headache (13.5%) and increased blood prolactin/hyperprolactinemia (18.0%); 8/178 (4.5%) participants experienced serious TEAEs, and 6/178 (3.4%) participants withdrew due to TEAEs. No deaths were reported. Conclusions The relapse rate observed with PP6M during the 2-year OLE was low (3.9%). Clinical and functional improvements demonstrated in the DB study were maintained during OLE, and no new safety concerns were identified.
引用
收藏
页码:537 / 544
页数:8
相关论文
共 50 条
[1]   Long-term safety and efficacy of armodafinil in bipolar depression: A 6-month open-label extension study [J].
Ketter, Terence A. ;
Amchin, Jess ;
Frye, Mark A. ;
Gross, Nicholas .
JOURNAL OF AFFECTIVE DISORDERS, 2016, 197 :51-57
[2]   Relapse Rates With Paliperidone Palmitate in Adult Patients With Schizophrenia: Results for the 6-Month Formulation From an Open-label Extension Study Compared to Real-World Data for the 1-Month and 3-Month Formulations [J].
Turkoz, Ibrahim ;
Daskiran, Mehmet ;
Siddiqui, Uzma ;
Knight, R. Karl ;
Johnston, Karen L. ;
Correll, Christoph U. .
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2024, 27 (02)
[3]   Three-Year Outcomes of 6-Month Paliperidone Palmitate in Adults With SchizophreniaAn Open-Label Extension Study of a Randomized Clinical Trial [J].
Correll, Christoph U. ;
Johnston, Karen ;
Turkoz, Ibrahim ;
Gray, Jason ;
Sun, Liping ;
Doring, Monica ;
Sajatovic, Martha .
JAMA NETWORK OPEN, 2024, 7 (07) :e2421495
[4]   Long-term safety and effectiveness of lurasidone in schizophrenia: a 22-month, open-label extension study [J].
Correll, Christoph U. ;
Cucchiaro, Josephine ;
Silva, Robert ;
Hsu, Jay ;
Pikalov, Andrei ;
Loebel, Antony .
CNS SPECTRUMS, 2016, 21 (05) :393-402
[5]   Long-term safety and durability of effect with a combination of olanzapine and samidorphan in patients with schizophrenia: results from a 1-year open-label extension study [J].
Yagoda, Sergey ;
Graham, Christine ;
Simmons, Adam ;
Arevalo, Christina ;
Jiang, Ying ;
McDonnell, David .
CNS SPECTRUMS, 2021, 26 (04) :383-392
[6]   Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study [J].
Cutler, Andrew J. ;
Durgam, Suresh ;
Wang, Yao ;
Migliore, Raffaele ;
Lu, Kaifeng ;
Laszlovszky, Istvan ;
Nemeth, Gyorgy .
CNS SPECTRUMS, 2018, 23 (01) :39-50
[7]   A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients With Schizophrenia [J].
Najarian, Dean ;
Sanga, Panna ;
Wang, Steven ;
Lim, Pilar ;
Singh, Arun ;
Robertson, Mary Jane ;
Cohen, Kristin ;
Schotte, Alain ;
Milz, Ruth ;
Venkatasubramanian, Raja ;
T'Jollyn, Huybrecht ;
Walling, David P. ;
Galderisi, Silvana ;
Gopal, Srihari .
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2022, 25 (03) :238-251
[8]   Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: Results from a 12-month open-label extension study [J].
Filts, Yuriy ;
Litman, Robert E. ;
Martinez, Javier ;
Anta, Lourdes ;
Naber, Dieter ;
Correll, Christoph U. .
SCHIZOPHRENIA RESEARCH, 2022, 239 :83-91
[9]   Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study [J].
Savitz, Adam J. ;
Xu, Haiyan ;
Gopal, Srihari ;
Nuamah, Isaac ;
Ravenstijn, Paulien ;
Janik, Adam ;
Schotte, Alain ;
Hough, David ;
Fleischhacker, Wolfgang W. .
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2016, 19 (07)
[10]   Long-Term Assessment of Lurasidone in Schizophrenia: Post Hoc Analysis of a 12-Month, Double Blind, Active-Controlled Trial and 6-Month Open-Label Extension Study [J].
Patel, Preeya J. ;
Weidenfeller, Christian ;
Jones, Andrew P. ;
Nilsson, Jens ;
Hsu, Jay .
NEUROLOGY AND THERAPY, 2021, 10 (01) :121-147